Since antisense oligonucleotides directed against XIAP are currently being evaluated in clinical trials and RING domain also is potent target of these agents [51], the results obtained from the current studies lead us to take a special consideration whether these drugs are able to target XIAP that is located in nucleus of cancer cells. Here, XIAP is linked to cancer.